Posts

Posted on

IHG® Army Hotels releases Earth Month tips for military travelers

Embedded focus on conservation and sustainability delivers $1.5 million in savings in recent years

PR Newswire

ATLANTA, April 5, 2021 /PRNewswire/ — IHG® Army Hotels, a unique portfolio of hotels located on 40 military installations in the U.S. and Puerto Rico, is encouraging military travelers to focus on conservation and sustainability during Earth Month this April. Protecting the planet for future generations through design and daily operations is a priority for IHG® Hotels & Resorts, the exclusive hotel operator and manager of IHG® Army Hotels, and for Lendlease, which owns the properties.

Additionally, over the past three years, conservation and sustainability efforts for the IHG Army Hotels estate have delivered savings of more than $1.5 million in electricity, gas, and water expenses. These cost savings are passed along to the U.S. Army’s Privatization of Army Lodging (PAL) program for future investment – including new hotel development and future renovations – across the IHG Army Hotels lodging portfolio.


Chuck Sourbeer, Head of Operations, IHG Army Hotels, commented: “Members of the military travel millions of miles every year to protect and serve our country, and we’re honored to provide a home away from home for them while they pursue their mission. We’re committed to minimizing the impact we have on the environment, and we invite all of our guests to join us in a commitment to reducing waste and conserving water and energy.”


Gretchen Turpen, SVP, Head of Lodging for Lendlease, commented: “Lendlease fully embraces innovation and finding sustainably responsible ways to provide well-built, well-maintained hotels designed to meet the unique needs of service members today and for generations to come. Through the PAL program, we have become an industry leader in deploying the use of Cross-Laminated Timber (CLT) as a key building material in constructing hotels across the U.S. The use of CLT on our construction sites provides sustainable benefits to include a lower carbon footprint. We look forward to delivering our fifth CLT hotel on Fort Jackson, SC, in June of this year.”

Tips released today include a variety of simple steps that military and civilian travelers can take to help reduce their environmental impact:

  • Don’t Waste Water – Take shorter showers and turn the faucet off at the sink while you shave or brush your teeth.
  • Use Energy as You Would at Home – When not in your room, turn off the lights and TV, and raise or lower the thermostat to conserve energy. Unplug phone and computer chargers that are not in use.
  • Skip Single Use – Avoid single-use plastics when on the road. Carry a water bottle with you while traveling and refill it at airport water fountains, and pack snacks in paper or a reusable container.
  • Consider Housekeeping Options – Many hotels, including IHG Army Hotels, give guests the option of reusing their towels and sheets rather than having them changed daily, reducing laundry and saving energy and water.
  • Keep Toiletries Out of the Trash – IHG Army Hotels offers bulk amenities for shampoo, conditioner, and body wash in many hotels, eliminating the need for single-use packaging for toiletries. If you choose to bring your own, be sure to pack them in reusable bottles instead of purchasing “travel size.”  

IHG Army Hotels and Lendlease integrate sustainability and conservation from the beginning, starting with the hotel’s building design and then the selection of building materials, fixtures, furniture, and equipment (FF&E) to culminate in operational efficiencies. Additionally, a comprehensive approach to energy efficiency is used that includes the materials selection process factoring in “embodied energy,” the energy needed to harvest, extract, process, manufacture, transport, construct, and maintain a material or product, and specifying FF&E materials that will last the duration of the product cycle, offering more opportunities for enhancing efficiencies.

Earlier this year, IHG launched Journey to Tomorrow, a series of ambitious new commitments to make a positive difference for people, communities, and planet over the next decade. The company has committed to reduce energy use and carbon emissions, pioneer the transformation to a minimal waste hospitality industry, and conserve water, and help secure water access in those areas at greatest risk. As a part of the IHG family, IHG Army Hotels has also committed to work towards the future of sustainable travel.

To learn more about IHG Army Hotels, or to book a stay, visit www.IHGArmyHotels.com. 


About IHG Hotels & Resorts


IHG Hotels & Resorts [LON:IHG, NYSE:IHG (ADRs)] is a global hospitality company, with a purpose to provide True Hospitality for Good.

With a family of 16 hotel brands and IHG Rewards, one of the world’s largest hotel loyalty programmes, IHG has nearly 6,000 open hotels in more than 100 countries, and a further 1,800 due to open over the next five years.

InterContinental Hotels Group PLC is the Group’s holding company and is incorporated in Great Britain and registered in England and Wales. Approximately 350,000 people work across IHG’s hotels and corporate offices globally.

Visit us online for more about our hotels and reservations and IHG Rewards. For our latest news, visit our Newsroom and follow us on LinkedIn, Facebook and Twitter.

About Lendlease
Lendlease is a leading global real estate group with operations in Australia, Asia, Europe and the Americas. Our purpose is to create value through places where communities thrive.

Headquartered in Sydney, Australia, and listed on the Australian Securities Exchange, Lendlease has approximately 9,500 employees internationally.

Our core capabilities are reflected in our operating segments of Development, Construction and Investments. The combination of these three segments provides us with a sustainable competitive advantage and allows us to provide innovative integrated solutions for our customers.

In the US, Lendlease’s Communities business is one of the nation’s leaders in public/private community development. We manage one of the largest military housing portfolios in the U.S. and are the Army’s exclusive partner for lodging. With a focus on creating sustainable value, Lendlease creates communities that regenerate our environment, enrich people’s lives and foster economic growth. Lendlease has worked extensively with the Department of Defense through the Military Housing Privatization Initiative (MHPI), a program that provides for the transfer of military housing assets to private sector companies. With over 40,000 residential units, 192 apartments and more than 12,000 hotel rooms in its portfolio, Lendlease will finance, develop, build, renovate and operate these sites for at least 50 years.

www.lendlease.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/ihg-army-hotels-releases-earth-month-tips-for-military-travelers-301262247.html

SOURCE IHG Hotels & Resorts

Posted on

Published Peer-Reviewed Data Demonstrate Bamlanivimab’s High Potency Against SARS-CoV-2 and Support its Use as a Foundational Antibody Therapy to Treat and Prevent COVID-19

Published Peer-Reviewed Data Demonstrate Bamlanivimab’s High Potency Against SARS-CoV-2 and Support its Use as a Foundational Antibody Therapy to Treat and Prevent COVID-19

– Bamlanivimab (LY-CoV555) has greater affinity and potency relative to other RBD-binding and ACE2-blocking antibodies tested in this study

– Because of its potency, bamlanivimab provides a therapeutic foundation to be administered with another antibody to expand the protection against viral variants

– Study was the first of its kind to show a neutralizing antibody can decrease SARS-CoV-2 viral shedding and transmission by blocking virus replication in the upper airway

– Bamlanivimab moved from first screen to clinical testing in 90 days1 and is the world’s first monoclonal antibody specifically developed against SARS-CoV-2 to receive FDA Emergency Use Authorization (EUA)2

– Since EUA, bamlanivimab has been used to treat approximately 400,000 high-risk COVID-19 patients in the U.S. alone and has been authorized in more than 15 countries

VANCOUVER, British Columbia–(BUSINESS WIRE)–
AbCellera (Nasdaq: ABCL) and collaborators today announced the publication of research in Science Translational Medicine characterizing the high potency of bamlanivimab (LY-CoV555) to neutralize SARS-CoV-2 by uniquely binding both the up and down confirmations of the spike receptor-binding domain (RBD) and inhibiting critical interactions with the angiotensin converting enzyme 2 (ACE2) cellular receptor necessary for viral entry. Data generated in a preclinical model showed prophylactic treatment with bamlanivimab resulted in significant decreases in viral load and replication in the upper and lower respiratory tracts after SARS-CoV-2 exposure, indicating the potential of bamlanivimab to reduce viral shedding and transmission. These data, which were generated prior to initiating clinical trials in June 2020 and published today, support the observed substantial clinical efficacy of bamlanivimab in treating and preventing COVID-19.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210405005386/en/

The unique binding of bamlanivimab to the SARS-CoV-2 spike protein: The spike protein exists as a trimer of three identical monomers on the surface of the SARS-CoV-2 virus. Structural modeling (left panel) of the spike trimer in shades of pink and white is shown with the target-binding fragments (Fabs) of bamlanivimab (in green and yellow) bound to the RBD of the spike protein. This analysis shows three bamlanivimab Fab fragments bound to one spike trimer. One of the spike proteins is in the up position (dark pink) with the other two in the down position (light pink and white). The middle panel shows an isolated view of the spike monomers (dark pink, white and light pink) with the bound bamlanivimab Fab fragments in green and yellow. In the right panel, two spike monomers bound in the up and down positions by the bamlanivimab Fab fragments are overlaid. 3D structural model provided by JS McLellan Group, University of Texas.

The unique binding of bamlanivimab to the SARS-CoV-2 spike protein: The spike protein exists as a trimer of three identical monomers on the surface of the SARS-CoV-2 virus. Structural modeling (left panel) of the spike trimer in shades of pink and white is shown with the target-binding fragments (Fabs) of bamlanivimab (in green and yellow) bound to the RBD of the spike protein. This analysis shows three bamlanivimab Fab fragments bound to one spike trimer. One of the spike proteins is in the up position (dark pink) with the other two in the down position (light pink and white). The middle panel shows an isolated view of the spike monomers (dark pink, white and light pink) with the bound bamlanivimab Fab fragments in green and yellow. In the right panel, two spike monomers bound in the up and down positions by the bamlanivimab Fab fragments are overlaid. 3D structural model provided by JS McLellan Group, University of Texas.

Previously Reported Clinical Trial Results

Bamlanivimab has been evaluated both alone and together with other antibodies in more than 5,000 patients across multiple clinical trials and is currently authorized in more than 15 countries. Bamlanivimab alone versus placebo has been shown to reduce hospitalization by 70% in high-risk patients with early COVID-19 infection3 and reduce the risk of contracting COVID-19 by up to 80% in nursing home residents when used as a prophylactic.4

Because of its potency, bamlanivimab also provides a therapeutic foundation to be administered with other antibodies to expand the protection against viral variants. The first of these, bamlanivimab together with etesevimab, has been authorized in the U.S. and within the European Union, and Phase 3 data show that this antibody therapy reduces COVID-19-related hospitalizations and death by 87%.5 Most importantly, across all the clinical trials, all COVID-19-related deaths occurred in patients taking the placebo; no deaths occurred in patients who received an antibody therapy, either bamlanivimab alone or together with another antibody.5

“At the beginning of our pandemic response to COVID-19, we made a decision with our partners and collaborators to develop a single antibody, emphasizing speed and scalability so that we would be able to help as many people as possible,” said Carl Hansen, Ph.D., CEO and President of AbCellera. “Over the past four months, bamlanivimab has been used to treat hundreds of thousands of people across the world — more than any other COVID-19 antibody therapy. We believe this has kept thousands of people out of the hospital, reducing the burden on our healthcare systems, and, most importantly, has saved thousands of lives.”

Discussion of Data Published Today in Science Translational Medicine

Data from multiple in vitro assays of the 24 lead antibodies identified by AbCellera and collaborators indicated bamlanivimab displayed greater neutralization potency despite similar RBD-binding affinities, suggesting bamlanivimab has a unique binding profile to the SARS-CoV-2 spike protein. Structural analysis using X-ray crystallography and electron microscopy demonstrated that bamlanivimab binds to an area on the spike protein overlapping the ACE2 binding site that is predicted to be fully accessible in both the up and down conformations. The RBD portion of the spike protein is the primary target for virus neutralization as it mediates the conserved mechanism of viral entry to infect cells. The spike exists in an up or down position, with the up position enabling interaction with the ACE2 receptor and the down position potentially contributing to immune system evasion. Regardless of the state of the spike protein, bamlanivimab has high binding potency to the RBD of SARS-CoV-2 spike protein.

“The unique ability of bamlanivimab to bind the spike protein in both the up and down position could underlie bamlanivimab’s greater neutralization potency compared to other antibodies,” said Bo Barnhart, Ph.D., Scientific Director at AbCellera. “These preclinical data show that modest doses of bamlanivimab provided protection against SARS-CoV-2 infection, which has since been confirmed in clinical trials to protect residents and staff in long-term care facilities and nursing homes. Neutralizing antibodies, like bamlanivimab, are designed to protect our most vulnerable populations for whom vaccines are less effective. These data with bamlanivimab further confirm that neutralizing antibodies have the potential to reduce SARS-CoV-2 viral transmission and prevent infection and can provide immediate benefit when a life-saving treatment is needed.”

To determine the potential of neutralizing antibodies to prevent SARS-CoV-2 infection, nonhuman primates (NHPs) were prophylactically treated with 1, 2.5, 15, or 50 mg/kg of bamlanivimab 24 hours prior to viral challenge. Critically, viral replication as well as viral load were significantly reduced in the upper respiratory tract on Day 1 at multiple doses. Additionally, viral load and replication were significantly reduced or undetectable in the lower respiratory tract at several doses. At doses of 2.5 mg/kg and higher serum concentrations were associated with maximal protection in this model.

“The data published today give insights into why bamlanivimab is so potent and further support all of our clinical experience and data showing that bamlanivimab is a safe and effective therapy to treat and prevent COVID-19, when administered early in the course of infection,” said Ester Falconer, Ph.D., Chief Technology Officer at AbCellera and senior author of the paper. “Furthermore, bamlanivimab’s unique potency allows for lower dosing and enables administration with another antibody to address SARS-CoV-2 variants. Over the past year, we have continued to screen patient samples, identifying thousands of human antibodies and generating massive amounts of information about how the human immune system responds to COVID-19. We have tracked the variants closely and identified a next-generation antibody that is predicted to neutralize all circulating variant strains of concern of SARS-CoV-2. This antibody, currently referred to as 1404, moved into preclinical development and manufacturing in January with our partner, Eli Lilly and Company, and we are continuing to work closely with them and our collaborators for rapid advancement.”

The preclinical data for bamlanivimab was published online today in Science Translational Medicine and can be found at: https://science.sciencemag.org/lookup/doi/10.1126/science.abf1906.

About AbCellera’s Response to COVID-19

Bamlanivimab was developed from an antibody that was discovered from the blood of a recovered COVID-19 patient using AbCellera’s pandemic response platform, in partnership with the Vaccine Research Center (VRC) at National Institute of Allergy and Infectious Diseases (NIAID). Within one week of receiving the sample, AbCellera screened over five million antibody-producing cells to identify and isolate approximately 500 unique antibodies that bind to SARS-CoV-2, the virus that causes COVID-19. The binding antibodies were then tested by AbCellera, the VRC, and Eli Lilly and Company (Lilly) to find those most effective in neutralizing the virus. Bamlanivimab was selected as the lead candidate from this group of antibodies and was the first therapeutic candidate specifically developed against SARS-CoV-2 to enter human clinical trials in North America. Bamlanivimab was the first monoclonal antibody to receive EUA from the FDA and is currently being assessed in several clinical trials alone and together with other antibodies.

AbCellera’s pandemic response capabilities were developed over the past three years as part of the Defense Advanced Research Projects Agency (DARPA) Pandemic Prevention Platform (P3) program. The goal of the P3 program is to establish a robust technology platform for pandemic response capable of developing field-ready medical countermeasures within 60 days of isolation of an unknown viral pathogen. AbCellera’s ongoing efforts to respond to the pandemic have identified more than 2,300 unique anti-SARS-CoV-2 human antibodies from multiple patient samples. These antibodies are in various stages of testing by AbCellera and its partners.

About Bamlanivimab (LY-CoV555)

Bamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus. Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Lilly scientists rapidly developed the antibody in less than three months after it was discovered by AbCellera and the scientists at NIAID VRC. It was identified from a blood sample taken from one of the first U.S. patients who recovered from COVID-19.

Lilly has successfully completed a Phase 1 study of bamlanivimab in hospitalized patients with COVID-19 (NCT04411628). A Phase 2/3 study in people recently diagnosed with COVID-19 in the ambulatory setting (BLAZE-1, NCT04427501) is ongoing. A Phase 3 study of bamlanivimab for the prevention of COVID-19 in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) is also ongoing. In addition, bamlanivimab is being tested in the National Institutes of Health-led ACTIV-2 study in ambulatory COVID-19 patients.

Bamlanivimab alone and together with etesevimab are authorized under special/emergency pathways, in the context of the pandemic, in the U.S. and the European Union. In addition, bamlanivimab alone is authorized for emergency use in Canada, Panama, Kuwait, the UAE, Israel, Rwanda, Morocco and numerous other countries. Through Lilly’s work with the Bill & Melinda Gates Foundation, Lilly is providing doses of bamlanivimab free of charge in Rwanda and Morocco.

About AbCellera Biologics Inc.

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, visit www.abcellera.com.

AbCellera Forward-looking Statements

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

__________________________

1 AbCellera’s Rapid Pandemic Response Platform Contributes to the World’s First COVID-19 Clinical Trial for a Potential Monoclonal Antibody Treatment. June 1, 2020. https://www.abcellera.com/news/2020-06-01-worlds-first-covid-19-clinical-trial-for-a-potential-monoclonal-antibody-treatment

2 AbCellera-Discovered Antibody Receives U.S. FDA Emergency Use Authorization as a Monotherapy for the Treatment of COVID-19, November 9, 2020. https://www.abcellera.com/news/2020-11-09-bamlanivimab-us-fda-eua

3 Interim Data Reported for AbCellera-Discovered COVID-19 Antibody in Phase 2 Clinical Trials

https://www.abcellera.com/news/2020-09-16-interim-data-phase-2-clinical-trials

4 AbCellera-Discovered Antibody Prevented COVID-19 in Nursing Homes and Reduced Risks by up to 80% for Residents, January 21, 2021. https://www.abcellera.com/news/2021-01-21-abcellera-discovered-antibody-prevented-covid-19-in-nursing-homes

5 AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalizations and Prevented Death in Phase 3 Trial for Early COVID-19, March 10, 2021. https://www.abcellera.com/news/2021-03-10-bamlanivimab-together-with-etesevimab-reduced-hospitalizations-and-prevented-death-in-phase-3-trial-for-early-covid-19

Source: AbCellera Biologics Inc.

Inquiries

Media: Jessica Yingling, Ph.D.; [email protected], +1(236)521-6774

Business Development: Kevin Heyries, Ph.D.; [email protected], +1(604)559-9005

Investor Relations: Melanie Solomon; [email protected], +1(778)729-9116

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Research Infectious Diseases Clinical Trials Biotechnology Health Pharmaceutical General Health Other Science Science

MEDIA:

Logo
Logo
Photo
Photo
The unique binding of bamlanivimab to the SARS-CoV-2 spike protein: The spike protein exists as a trimer of three identical monomers on the surface of the SARS-CoV-2 virus. Structural modeling (left panel) of the spike trimer in shades of pink and white is shown with the target-binding fragments (Fabs) of bamlanivimab (in green and yellow) bound to the RBD of the spike protein. This analysis shows three bamlanivimab Fab fragments bound to one spike trimer. One of the spike proteins is in the up position (dark pink) with the other two in the down position (light pink and white). The middle panel shows an isolated view of the spike monomers (dark pink, white and light pink) with the bound bamlanivimab Fab fragments in green and yellow. In the right panel, two spike monomers bound in the up and down positions by the bamlanivimab Fab fragments are overlaid. 3D structural model provided by JS McLellan Group, University of Texas.
Posted on

Bank of Marin Bancorp to Webcast Q1 Earnings on Monday, April 19 at 8:30 a.m. PT

Bank of Marin Bancorp to Webcast Q1 Earnings on Monday, April 19 at 8:30 a.m. PT

NOVATO, Calif.–(BUSINESS WIRE)–
Bank of Marin Bancorp (Nasdaq: BMRC) will present its first quarter earnings call via webcast on Monday, April 19, 2021 at 8:30 a.m. PT/11:30 a.m. ET.

All interested parties are invited to listen to President and Chief Executive Officer Russell A. Colombo, Executive Vice President and Chief Operating Officer Tim Myers, Executive Vice President and Chief Financial Officer Tani Girton, and Executive Vice President and Chief Credit Officer Beth Reizman, who will discuss the highlights of the Company’s fiscal first quarter, which ended March 31, 2021.

Investors will have the opportunity to listen to the webcast online through Bank of Marin’s website at https://www.bankofmarin.com under “Investor Relations.” To listen to the webcast live, please go to the website at least 15 minutes early to register, download and install any necessary audio software. For those who cannot listen to the live broadcast, a replay will be available at the same website location shortly after the call.

About Bank of Marin Bancorp

Founded in 1990 and headquartered in Novato, Bank of Marin is the wholly owned subsidiary of Bank of Marin Bancorp (Nasdaq: BMRC). A leading business and community bank in the San Francisco Bay Area, with assets of $2.9 billion as of December 31, 2020, Bank of Marin has 21 branches and 7 commercial banking offices located across 7 Bay Area counties. Bank of Marin provides commercial banking, personal banking, specialty lending and wealth management and trust services. Specializing in providing legendary service to its customers and investing in its local communities, Bank of Marin has consistently been ranked one of the “Top Corporate Philanthropists” by the San Francisco Business Times and one of the “Best Places to Work” by the North Bay Business Journal. Bank of Marin Bancorp is included in the Russell 2000 Small-Cap Index and Nasdaq ABA Community Bank Index. For more information, go to www.bankofmarin.com.

BMRC-ER

Beth Drummey

Marketing & Corporate Communications Manager

Bank of Marin

415-763-4529 | [email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Posted on

New Digital Platform for Washington Place Provides Enhanced Access to Historic Home in Honolulu

New Digital Platform for Washington Place Provides Enhanced Access to Historic Home in Honolulu

HONOLULU–(BUSINESS WIRE)–
The Department of Accounting and General Services (DAGS) and NIC Hawaii have launched a new website allowing people to learn more about the history, inhabitants and legacy of Washington Place. Best known as the home of Hawaiʻi’s beloved Queen Liliʻuokalani, this National Historic Landmark was the only official residence of a state governor in the United States that was also home to a monarch.

A primary feature on the new site is the addition of online forms that allow people to submit requests for tours, filming, events or volunteering. The site also serves as a virtual museum, providing visitors a glimpse inside the home with its unique collection of art and artifacts including paintings, furniture and more. Finally, a historical timeline highlights events as well as the special guests who have visited the home throughout current and previous generations.

NIC Hawaii worked closely with the Department of Accounting and General Services (DAGS) to design the new website. Built in WordPress, the site has a responsive web design that works across all mobile and tablet devices, and agency staff can easily manage the web content going forward.

“As a longtime partner with DAGS, we were thrilled to collaborate with stakeholders from across the State of Hawaiʻi to quickly build a site to meet their needs,” said Rosie Warfield, NIC Hawaii Manager of eGovernment Services. “We think residents and visitors will be delighted to dive in and discover more about the history behind this home.”

As Washington Place begins to reopen to the public following the COVID-19 pandemic, the site will be re-introducing tours, both virtual and in-person, and creating more virtual programs that will be shared via an event calendar.

About DAGS

The Department of Accounting and General Services, commonly known as DAGS, is headed by the State Comptroller, Curt T. Otaguro, who concurrently serves as the director of DAGS. The department is responsible for managing and supervising a wide range of state programs and activities.

About NIC Hawaii

NIC Hawaii is a division of national digital government solutions firm NIC Inc, and is a part of the eHawaii.gov state portal program. Pursuant to chapter 27G, Hawaii Revised Statutes, the portal program is overseen by the Access Hawaiʻi Committee, which collaborates with provider NIC Hawaii (formerly Hawaii Information Consortium (HIC)), along with state and county agencies to continually identify new online services to be added to the portal. For more information, visit nichawaii.egov.com.

About NIC

NIC (Nasdaq: EGOV) is a leading digital government solutions and payments company, serving more than 7,800 federal, state and local government agencies across the nation. With headquarters in Olathe, Kansas, and offices in more than 30 states, NIC partners with government to deliver user-friendly digital services that make it easier and more efficient to interact with government – providing valuable conveniences such as applying for unemployment insurance, submitting business filings, renewing licenses, accessing information and making secure payments without visiting a government office. In 2020, NIC securely processed 402 million online transactions and more than $24 billion on behalf of government agencies. In response to the COVID-19 pandemic, NIC also developed 130 new solutions to address crisis communications, pandemic unemployment, COVID-19 testing and vaccine scheduling. Learn more at www.egov.com.

Contact: Burt Ramos | NIC Hawaii

General Manager

808-695-4616 | [email protected]

Kara Cowie | NIC Inc

Director of Corporate Communications

816-813-2350 | [email protected]

KEYWORDS: Hawaii United States North America

INDUSTRY KEYWORDS: Public Policy/Government State/Local Technology Mobile/Wireless Software Internet

MEDIA:

Logo
Logo
Posted on

Avadyne Health Joins Healthcare Revenue Cycle Leader Meduit to Expand National Footprint and Accelerate Growth

CHARLOTTE, N.C., April 05, 2021 (GLOBE NEWSWIRE) — Meduit, one of the top five healthcare revenue cycle solutions companies in the country, announced today that Avadyne Health, headquartered in Moline, IL, has joined forces with Meduit. Together, the two companies will leverage their combined broad and complementary revenue cycle management (RCM) capabilities to fuel strategic growth in the healthcare sector.

Established nearly 50 years ago, Avadyne Health delivers expertise in patient payment and financial engagement with a complete solution that addresses the needs of patients. They can scale self-pay account resolution and bad debt recovery services for multi-hospital networks to the largest health systems in the country. Avadyne Health manages over $3 billion in placements, serves over 5 million patients and collects over $1 billion in patient payments annually.

“The Avadyne Health team delivers optimal patient financial experiences delivered by a caring staff,” said Jayson Yardley, Avadyne CEO. “By joining the Meduit team, we’ll be able to leverage our broad and complementary solutions to serve more patients and providers with state-of-the art services that lower the cost to collect and increase provider collections.”

As one of the leading revenue cycle solutions companies in the nation, Meduit makes vital contributions to the financial, operational and clinical health of hospitals and large physician practices by delivering expert, efficient and innovative RCM solutions. In addition to its proven healthcare-focused RCM solutions, Meduit is also widely regarded as a pioneer in artificial intelligence and robotic process automation solutions for healthcare RCM.

“With its national presence and depth of expertise, the Avadyne Health team will expand Meduit’s geographic footprint further,” said Jeff Nieman, CEO of Meduit. “Together, our two teams will be able to serve more hospitals and physician groups with solutions that are a win-win for both patients and providers.”

For more information, visit: https://hub.meduitrcm.com/avadyne

About Meduit

Meduit is one of the nation’s leading revenue cycle solutions companies with decades of experience in the RCM arena, serving more than 850 hospitals and physician practices in 47 states. Meduit combines a state-of-the-art accounts receivable management model with advanced technologies and an experienced people-focused team that takes a compassionate and supportive approach to working with patients. Meduit significantly improves financial, operational and clinical performance, ensuring that healthcare organizations can dedicate their resources to providing more quality healthcare services to more patients. For more information, please visit www.meduitrcm.com.


Contact:


Chris Cooney
407-921-6932
[email protected] 



Posted on

Matthew Remo is Promoted to Senior Vice President, Director of Strategy and Development at Peapack-Gladstone Bank

Bedminster, NJ, April 05, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Peapack-Gladstone Financial Corporation (NASDAQ Global Select Market:  PGC) and Peapack-Gladstone Bank announce the elevation of Matthew Remo to Senior Vice President, Director of Strategy and Development at Peapack-Gladstone Bank.  In his current role, Mr. Remo is responsible for the development and formalization of the Company’s business strategy, the identification of critical objectives and priorities, and the expansion of data analytics/management information systems to measure and report progress.  Mr. Remo is also responsible for ensuring that the scope of enterprise risk management activities, including capital, liquidity, and credit, aligns with the Bank’s defined business strategies.  Matt continues to lead new markets and products governance and serves on many of the Company’s committees.

Mr. Remo joined Peapack-Gladstone Bank in 2019 as vice president, senior enterprise risk officer and was promoted to the position of vice president, director of strategy development in October of 2020.  During his tenure at the Bank, Matt has made significant contributions across many areas including capital and strategic planning, credit reviews, equipment finance, regulatory compliance, enterprise risk management, digital initiatives, new product governance, and served a significant role in the Bank’s Paycheck Protection Program lending efforts. 

Mr. Remo joined Peapack-Gladstone Bank after an accomplished 10-year career with the Federal Reserve Bank of New York (FRBNY).  As senior examiner of large banking organizations, he specialized in capital and strategic planning, wealth management, asset-liability management and stress testing.  Prior to that, he was supervisory manager of regional and community banks, where he managed safety and soundness examination teams and led technology design and implementation efforts across the Second District of the Federal Reserve Bank.  

Matt graduated from the University of Connecticut with a Bachelor of Science in Business Administration, Finance and a Certificate in Management Information Systems.  He holds his Safety and Soundness Examiner Commissioning with the Federal Reserve Board of Governors.  In 2020, Matt was recognized by NJBankers as a “Rising Star” of the New Jersey banking industry.

About Peapack-Gladstone Bank

Founded in 1921, Peapack-Gladstone Financial Corporation is a NJ bank holding company with total assets of $5.9 billion and wealth management assets under management and/or administration of $8.8 billion as of December 31, 2020.  Peapack-Gladstone Bank is a commercial bank that provides innovative wealth management, investment banking, commercial and retail solutions, including residential lending and online platforms, to businesses and consumers.  Peapack Private, the Bank’s wealth management division, offers comprehensive financial, tax, fiduciary and investment advice and solutions, to individuals, families, privately held businesses, family offices and not-for-profit organizations, which help them establish, maintain and expand their legacy.  Together, Peapack-Gladstone Bank and Peapack Private offer an unparalleled commitment to client service.  Visit www.pgbank.com and www.peapackprivate.com for more information.

Contact:  Rosanne Schwab, Peapack-Gladstone Bank, Assistant Vice President, Public Relations and Corporate Communications Manager, 500 Hills Drive, Suite 300, Bedminster, NJ  07921 [email protected], (908) 719-6543.

Attachment



Posted on

Packaging Corporation of America Schedules Conference Call to Discuss First Quarter 2021 Operating Results

Packaging Corporation of America Schedules Conference Call to Discuss First Quarter 2021 Operating Results

LAKE FOREST, Ill.–(BUSINESS WIRE)–
Packaging Corporation of America (NYSE: PKG) will hold a conference call on Tuesday, April 27, 2021 at 9:00 a.m. Eastern Time to discuss first quarter 2021 results. First quarter earnings results will be released after the market closes on Monday, April 26, 2021.

To access the conference call, please dial (855) 730-0288 (U.S. and Canada) or (832) 412-2295 (International) by 8:45 a.m. (Eastern Time). The conference call leader will be Mark Kowlzan, and the conference ID is 4555529.

A replay of the call will also be available from 12:00 p.m. (Eastern Time) on April 27, 2021 until 11:59 p.m. (Eastern Time) on May 11, 2021. To access the recording, please dial (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (International). The passcode is 4555529.

This call will also be webcast and accessible at PCA’s website at www.packagingcorp.com.

PCA is the third largest producer of containerboard products and the third largest producer of uncoated freesheet paper in North America. PCA operates eight paper mills and 90 corrugated products plants and related facilities.

Barbara Sessions

Packaging Corporation of America

INVESTOR RELATIONS: (877) 454-2509

PCA Web Site: www.packagingcorp.com

KEYWORDS: Illinois United States North America

INDUSTRY KEYWORDS: Other Transport Office Products Packaging Transport Manufacturing Forest Products Logistics/Supply Chain Management Supply Chain Management Retail Natural Resources

MEDIA:

Posted on

Amazon, Walmart.com Carry Heavy-Duty, Industrial-Strength Reinol Original Hand Cleaner That Has Cleaned The Greasiest Hands for 100 Years

Solvent-Free Reinol Soap is Perfect for All Industrial Workers

PALM BEACH, FL, April 05, 2021 (GLOBE NEWSWIRE) — Amazon and Walmart.com carry an overnight soap sensation that has been cleaning the dirtiest and greasiest industrial workers’ hands for 100 years. 

“Reinol Original Hand Cleaner has passed the test of time ten times over,” said Clive Leon, founder and chairman of Reinol, the solvent-free, heavy-duty soap manufacturer. “It was developed in the early 1900s. Any product that has been around for 100 years has proven itself effective.”

Leon said Reinol is ready for its second century.

“We decided it was time to help clean the hands of American workers,” Leon said, adding that having Amazon and Walmart.com has allowed Reinol to reach a large swath of consumers in the United States.

Leon said Reinol is also the perfect soap for the pandemic- and post-pandemic era.

“For the past 12 months, everyone has been washing their hands more often than ever before,” Leon said. “Reinol is soft and gentle on your skin compared to many hand cleaners that contain solvents and harsh chemicals.”

Many soaps continue to contain dangerous ingredients, such as mineral spirits, kerosene, white spirits, and naphtha.

“These chemicals can damage your hands. Reinol has always been a gentle, but effective, hand cleaner for ten decades,” Leon said.

Reinol’s formula, which dates back to the early 1900s, only uses soft soaps, oils, and no harsh solvents. It also contains specially selected fine rounded degerminated inert quartz silica sand, which helps pick the dirt off the skin.

Reinol also is inexpensive to use. Just rub a level teaspoon full of Reinol into your hands, add a few drops of water, lather, and rinse thoroughly. A one-liter tub should wash 300 pairs of hands. Reinol recently introduced a dispenser that gives you the exact amount of soap you need to clean your hands.

“We are getting the word out to American consumers that Reinol is the best option to get your hands cleaned and healthy,” Leon said.

To purchase Reinol Original Hand Cleaner, visit Walmart.com or Amazon.com.

Attachments 



Robert Grant
Reinol Original Hand Cleaner
561-421-3045
[email protected]

Posted on

SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Canoo Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Canoo Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES–(BUSINESS WIRE)–The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Canoo Inc. (“Canoo” or “the Company”) (NASDAQ: GOEV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between August 18, 2020 and March 29, 2021, inclusive (the ”Class Period”), are encouraged to contact the firm before June 1, 2021.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Canoo shifted away from its previous focus on selling vehicles using a subscription model. The Company’s engineering services would not provide meaningful revenue in 2021, or reduce operational risk. As a result, the Company would shift its focus away from the engineering services business as well. The Company did not have partnerships with original equipment manufacturers (OEMs) and was not engaging in its previously announced partnership with Hyundai. Based on these facts, the Company’s public statements were false and materially misleading. When the market learned the truth about Canoo, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

The Schall Law Firm

Brian Schall, Esq.,

www.schallfirm.com

Office: 310-301-3335

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo
Posted on

Aqua Texas and Essential Foundation Donate $50,000 to Support Winter Storm Recovery Efforts in Texas

Aqua Texas and Essential Foundation Donate $50,000 to Support Winter Storm Recovery Efforts in Texas

AUSTIN, Texas–(BUSINESS WIRE)–
Aqua Texas today announced that it has donated $50,000 to three food banks, three American Red Cross chapters, and three Salvation Army centers across its service territory to provide community support in response to the devastating effects of February’s severe winter weather.

  • Aqua donated a total of $15,000 to the Montgomery County Food Bank in Conroe; the Crisis Bread Basket in Wimberley, Hays County; and People Helping People in Granbury, Hood County.
  • Aqua donated a total of $17,500 to the Dallas-Fort Worth, Central Texas and Greater Houston chapters of the American Red Cross.
  • Aqua donated a total of $17,500 to the Irving Branch, Austin Command Center and Houston Command Center of the Salvation Army.

“At Aqua Texas, we are proud to come together in support of organizations that provide assistance in the communities we serve,” said Aqua Texas President Bob Laughman. “We hope these contributions will help some of those who need it the most.”

Aqua Texas serves about 200,000 people in 54 counties statewide. Visit Aqua online at AquaAmerica.com, facebook.com/MyAquaAmerica, and twitter.com/MyAquaAmerica.

Gretchen Toner

484.368.4816

[email protected]

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Philanthropy Other Natural Resources Utilities Energy Natural Resources Foundation

MEDIA:

Logo
Logo